Pfizer Inc. (PFE - Get Report) retreated 0.2% after market close, after announcing it would break into three, more specialized businesses focusing on innovative medicines, established medicines and consumer healthcare by 2019.

"We think this news is positive for PFE and underscores our view that the company's long-term growth prospects are underappreciated as the impact of LOE headwinds diminish in 2020," says Louise Chen, an analyst at Cantor Fitzgerald on July 11. "We think respectable earnings growth, driven by Innovative Health, pipeline advancements, and return of capital to PFE's shareholders--above the industry average--are all underappreciated."

"This new structure represents a natural evolution of these businesses given the ongoing strength of our in-market products and our late-stage pipeline," said Ian Read, chief executive officer in a company statement. "Post 2020, we see this structure better positioning each business to achieve its growth potential."

Pfizer's new Innovative Medicines business would position the company for strong growth because of the growing appetite of an aging population to save on prescription meds, Read noted. Pfizer is positioning the unit, which is expected to account for 75% of the company's revenues, to account for its loss of exclusivity for Lyrica, a trademarked drug for treating epilepsy, neuropathic pain, anxiety disorders and other conditions.

The Established Medicine group will continue production and marketing of Pfizer's off-patent legacy brands including Lyrica, Lipitor, Norvasc and Viagra as well as generic medicines, according to the announcement.

The consumer healthcare business, which will include all Pfizer's over-the-counter medicines, will "operate relatively autonomously with dedicated manufacturing and regulatory capabilities" the announcement said.

On Monday July 9, Pfizer's stock dipped after a tweet by President Donald Trump targeted the company for raising its many of its drug prices for, "no reason."

On that day, Pfizer shares were trading at about $37.43 before Trump's tweet, but the stock fell after the tweet to $37.19 during Monday trading before closing up 0.13%.

On Tuesday the company deferred the plan to raise drug prices by six months after meeting with Trump about his criticism.

Trump then applauded the company for announcing the price hike delay.

"Just talked with Pfizer CEO and @SecAzar on our drug pricing blueprint. Pfizer is rolling back price hikes, so American patients don't pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!," Trump wrote.

What's Next for Pfizer? Access Real Money Analysis Here:

Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff

Pfizer Doesn't Look Fundamentally or Technically Strong

Pfizer Is Not at a Buy Point, but Here's an Options Play on the Name: Tim Collins